PDS Biotech to Host Oct. 15 KOL Event on PDS0301 in Metastatic Colorectal Cancer

PDS Biotechnology Corp

PDS Biotechnology (Nasdaq: PDSB) will host a virtual KOL event on October 15, 2026, at 8:00 AM ET featuring NCI/CCR investigator Jonathan M. Hernandez, M.D.
Event covers clinical outcomes from PDS0301 Phase 2 trials in advanced liver-associated cancers, focusing on the metastatic colorectal cancer (mCRC) cohort.
PDS0301 is an investigational IL-12 immunocytokine designed to bind necrotic DNA in tumors and deliver IL-12 to promote T cell and NK cell infiltration.
Trial population includes second- and third-line unresectable microsatellite stable (MSS) or mismatch repair-proficient (pMMR) colorectal liver metastases, the majority of mCRC.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.